News Mulvany hits the reset button at BenevolentAI The shape of BenevolentAI following the return of co-founder Ken Mulvany has started to crystallise and could see the company return to private hands.
News Refiling for cALD therapy on the cards after new data Readout from NEXUS study sets up mid-2025 refiling for Minoryx and Neuraxpharm's leriglitazone for rare disease cerebral adrenoleukodystrophy (cALD).
News Drug-digital dual therapy for depression starts phase 2 Gate Neurosciences' antidepressant apimostinel has started a proof-of-concept study to see if its efficacy can be boosted by a digital training tool.
News uniQure rockets on map to market for Huntington's therapy uniQure says it has reached agreement with the FDA on a pathway to accelerated approval for its much-anticipated Huntington's disease gene therapy.
News ASH: Stem cell transplant study exposes US zip-code lottery Access to a stem cell transplant in the US - and the chances of surviving it - depends on social and economic factors, finds a new study.
News MSD gets first positive trial of Keytruda/Lynparza combo After a string of trial failures, MSD claims a partial win for Keytruda and Lynparza in advanced epithelial ovarian cancer.
News Lilly adds another sales channel for obesity drug Zepbound Telehealth firm Ro will offer low-cost, single-dose vials of Lilly's obesity drug Zepbound, the first alternative to the new LillyDirect DTC channel.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.